Sentinal4D uses AI to analyze tumor cells at a single-cell level, providing personalized diagnoses for cancer patients. This enables the development of targeted cancer therapies based on individual tumor characteristics.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery methods often rely on static, two-dimensional cell cultures, failing to capture the complex, dynamic behavior of cells in their native three-dimensional microenvironment. This can lead to inaccurate predictions of drug efficacy and the development of therapies that ultimately fail in clinical trials. Furthermore, analyzing cellular behavior at a single-cell level is challenging, hindering the development of personalized cancer treatments.
Solution
Sentinal4D addresses these limitations by combining AI with 3D and 4D cell biology to accelerate oncology drug discovery and development. The company's platform uses deep learning to analyze the morphological profiles of cells in three dimensions, over time, providing a more holistic view of cellular biology. By simulating how individual cells behave over time in response to therapy, Sentinal4D's AI models can identify hidden vulnerabilities and predict treatment outcomes with greater accuracy. This approach enables the development of novel cancer therapy candidates with a higher probability of clinical success and facilitates the creation of personalized treatments tailored to individual tumor characteristics.
Target Audience
Sentinal4D's primary customers are biotechnology and pharmaceutical companies involved in oncology drug discovery and development, as well as researchers and clinicians seeking personalized cancer treatments.
Features
- AI-powered analysis of 3D and 4D cellular morphodynamics
- Geometric deep learning and multiple-instance learning for 3D cell-shape profiling
- Prediction of protein co-membership across multiple curated databases
- Generative AI models to simulate cell behavior over time in response to therapy
- Identification of drug mechanisms and off-target effects
- Virtual simulation of drug effects to accelerate drug testing
- Light-sheet OPM microscopy for 3D imaging of melanoma cells